Compare ARVN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | PACB |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 521.8M |
| IPO Year | 2018 | 2010 |
| Metric | ARVN | PACB |
|---|---|---|
| Price | $8.27 | $1.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 3 |
| Target Price | ★ $15.05 | $1.67 |
| AVG Volume (30 Days) | 711.6K | ★ 5.6M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | $93,468,000.00 |
| Revenue This Year | N/A | $11.32 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | $4.89 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $6.97 | $1.07 |
| 52 Week High | $14.22 | $2.73 |
| Indicator | ARVN | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 38.71 | 52.02 |
| Support Level | $7.90 | $1.27 |
| Resistance Level | $8.40 | $1.47 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 11.88 | 59.46 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.